260
0.00%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Taiko Pharmaceutical Co
Its shares trade on Tokyo Stock Exchange under the ticker 4574.T. It has been listed since 18 March 2009. In the fiscal year to 31 December 2024, it reported revenue of ¥6.29bn and net income of ¥898.0m. At that date it held total assets of ¥12.91bn and shareholders' equity of ¥7.96bn.
Taiko Pharmaceutical Co., Ltd. engages in the manufacture and sale of general medications particularly non-prescription gastrointestinal drugs and designated quasi drugs. The company is headquartered in Osaka, Osaka-Fu. The company went IPO on 2009-03-18. The firm is engaged in three business segments. The Pharmaceutical Product segment is engaged in the manufacturing, sales and export of gastrointestinal drugs under the name SEIROGAN, SEIROGAN TOI-A (sugar coated tablet) and PISHUT. The Infection Control segment is engaged in the planning, development and sales of infection control products, which apply proprietary technique regarding chlorine dioxide gas. The Others segment is engaged in the manufacturing and sales of bath liquid, soap and gardening pyroligneous acid.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 18 Mar 2009
- Employees
- 210
- Website
- seirogan.co.jp ↗
Leadership
Pay as last reported
- Mr. Hitoshi ShibataChairman of the Board, Representative Director, since 1980
- Dr. Takashi ShibataPresident, Chief Executive Officer, Representative Director, since 1998
- Mr. Masaji HashimotoSenior Managing Director, since 2020
- Mr. Kento DoiIndependent Director
- Mr. Tetsuo MiwaIndependent Director
- Mr. Toshihide TominagaIndependent Director
- Mr. Toru NakajoDirector of Accounting, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Taiko Pharmaceutical manufactures SEIROGAN for gastrointestinal issues in Japan.
- The company's Infection Control segment uses proprietary chlorine dioxide gas technology.
- Taiko Pharmaceutical's Others segment produces bath liquids and gardening pyroligneous acid.
Weaknesses
- Taiko Pharmaceutical has only 210 employees in Osaka, Japan.
- The company's business is limited to three segments in the Health Care sector.
- Taiko Pharmaceutical's IPO was in 2009, indicating a long-standing presence.
Opportunities
- Taiko Pharmaceutical can expand SEIROGAN sales in the Japanese market.
- The Infection Control segment may grow with increasing demand for disinfection products.
- The Others segment could explore new markets for bath liquids and gardening products.
Threats
- Taiko Pharmaceutical faces competition from other Japanese pharmaceutical companies.
- The Health Care sector in Japan is highly regulated and competitive.
- The company's reliance on gastrointestinal drugs may limit growth opportunities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.